Open-label extension study of vericiguat in pediatric heart failure with left ventricular systolic dysfunction

Phase 3, open-label, single-arm trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event and Number of participants who discontinue study treatment due to an adverse event. Started Jul 2024; status: completed.